These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28581634)

  • 101. Impact of Steroids on Natural Killer Cells Against Cytotoxicity and Hepatitis C Virus Replication.
    Ohira M; Nishida S; Tryphonopoulos P; Ruiz P; Ohdan H; Tzakis AG
    Transplant Proc; 2017 Jun; 49(5):1160-1164. PubMed ID: 28583548
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
    Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis.
    Morisawa N; Koshima Y; Kuriyama S; Matsuyama M; Hayashi N; Satoh JI; Amemiya M; Yokoo T
    Nephrology (Carlton); 2017 Jul; 22(7):562-565. PubMed ID: 28621007
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.
    Lens S; Fernández I; Rodríguez-Tajes S; Hontangas V; Vergara M; Forné M; Calleja JL; Diago M; Llaneras J; Llerena S; Torras X; Sacristán B; Roget M; Fernández-Rodríguez CM; Navascués MC; Fuentes J; Sánchez-Ruano JJ; Simón MÁ; Sáez-Royuela F; Baliellas C; Morillas R; Forns X;
    Am J Gastroenterol; 2017 Sep; 112(9):1400-1409. PubMed ID: 28585554
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population.
    Kim BH; Lim YS; Kim EY; Kong HJ; Won YJ; Han S; Park S; Hwang JS
    J Gastroenterol Hepatol; 2018 Feb; 33(2):475-483. PubMed ID: 28612951
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Does steatosis affect the performance of diffusion-weighted MRI values for fibrosis evaluation in patients with chronic hepatitis C genotype 4?
    Besheer T; Razek AAKA; El Bendary M; Abd El Maksoud M; Elalfy H; Zalata K; Elkashef W; Zaghloul H; El Gilany AH
    Turk J Gastroenterol; 2017 Jul; 28(4):283-288. PubMed ID: 28594328
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?
    Enomoto M; Murakami Y; Kawada N
    Gastroenterology; 2017 Jul; 153(1):327-328. PubMed ID: 28583840
    [No Abstract]   [Full Text] [Related]  

  • 108. A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scores.
    Korell J; Green B; DeVincenzo J; Huntjens D
    Eur J Pharm Sci; 2017 Nov; 109S():S154-S160. PubMed ID: 28606804
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Optimal timing for hepatitis C antiviral therapy in the peritransplant period?
    Cholankeril G; Wong RJ; Kim D; Ahmed A
    Hepatology; 2017 Sep; 66(3):1004. PubMed ID: 28586088
    [No Abstract]   [Full Text] [Related]  

  • 110. Reply.
    Chhatwal J; Samur S; Bethea E; Chung RT
    Hepatology; 2017 Sep; 66(3):1005-1006. PubMed ID: 28586089
    [No Abstract]   [Full Text] [Related]  

  • 111. Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project.
    Dong BJ; Lopez M; Cocohoba J
    J Am Pharm Assoc (2003); 2017; 57(4):510-515.e2. PubMed ID: 28602784
    [TBL] [Abstract][Full Text] [Related]  

  • 112. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
    Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
    HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
    [TBL] [Abstract][Full Text] [Related]  

  • 113. New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an Addiction series.
    Hickman M; Grebely J; Bruneau J; Coffin P; Degenhardt L; Hutchinson S; Larney S; Martin N; Treloar C; Vickerman P
    Addiction; 2017 Jul; 112(7):1126-1127. PubMed ID: 28586551
    [No Abstract]   [Full Text] [Related]  

  • 114. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure.
    Walker A; Filke S; Lübke N; Obermeier M; Kaiser R; Häussinger D; Timm J; Bock HH
    Virol J; 2017 Jun; 14(1):106. PubMed ID: 28595606
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
    Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
    J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus.
    Hum J; Jou JH; Green PK; Berry K; Lundblad J; Hettinger BD; Chang M; Ioannou GN
    Diabetes Care; 2017 Sep; 40(9):1173-1180. PubMed ID: 28659309
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
    Voaklander R; Jacobson IM
    Expert Rev Gastroenterol Hepatol; 2017 Sep; 11(9):789-795. PubMed ID: 28673106
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Hepatitis B and C virus infection and diabetes mellitus: A cohort study.
    Hong YS; Chang Y; Ryu S; Cainzos-Achirica M; Kwon MJ; Zhang Y; Choi Y; Ahn J; Rampal S; Zhao D; Pastor-Barriuso R; Lazo M; Shin H; Cho J; Guallar E
    Sci Rep; 2017 Jul; 7(1):4606. PubMed ID: 28676706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.